TSE:4569Pharmaceuticals
Kyorin Pharmaceutical (TSE:4569) Margin Improvement To 8.1% Challenges Bearish Profitability Narratives
KYORIN Pharmaceutical (TSE:4569) has reported Q3 2026 revenue of ¥33,725 million and basic EPS of ¥45.69, with trailing twelve month EPS at ¥187.40 on revenue of ¥133,257 million. This sets a clear profit focused tone for this update. The company has seen quarterly revenue move from ¥26,720 million in Q2 2025 to ¥33,725 million in Q3 2026, while basic EPS has ranged from ¥6.44 in Q2 2025 to ¥45.69 in the latest quarter and ¥187.40 on a trailing twelve month basis. This gives investors a...